FRCA Notes


Spinal Cord Stimulators

Curriculum

There is no specific curriculum item for this topic, although it probably falls under knowing "the role of interventional procedures for pain relief".

Despite no previous CRQs on the topic, three BJA Education articles in the past decade seems like fertile hunting ground for those writing questions.

Resources



  • Chronic neuropathic pain >6 months and pain score >5/10 despite optimal conventional medical management, following successful trial of stimulation
  • Examples include:

  • Effective only in a small, highly selected group of patients
  • Should be viewed as a palliative intervention: aims to reduce suffering and improve function and quality of life rather than cure
  • Delivered as part of a multimodal, multidisciplinary biopsychosocial model of care

  • Systemic infection or sepsis
  • Existing implanted medical (cardiac) device e.g. PPM, ICD
  • Immunosuppressed state
  • Uncontrolled bleeding or anticoagulation
  • Psychological unsuitability e.g. severe depression, anxiety, personality disorder

Components

  • Implantable pulse generator (IPG)
    • Placed externally for the trial period
    • If successful, implanted internally in the subcutaneous space e.g. abdominal wall, gluteal, infraclavicular areas
    • Rechargeable IPGs: longer lifespan (median ~7 years); suitable for most patients who can reliably recharge them
    • Primary cell (non-rechargeable) IPGs: shorter lifespan (median ~4 years); preferred in cognitive impairment, physical disability or limited prognosis

  • Implanted electrodes (stimulator leads)
    • 4-8 electrodes
    • Either catheters (percutaneously placed) or paddles (surgically placed)
    • Lie in the epidural space over the dorsal columns, typically in the thoracic spine
    • Exact placement varies depending on the clinical condition being treated

  • Wireless systems are emerging: implanted leads with an integrated receiver powered by an external transmitter, avoiding the need for an IPG
  • Programming can increasingly be performed remotely, without an in-person visit

Mode of action

  • Stimulation activates large-diameter, myelinated Aβ fibres in the dorsal columns, which conduct impulses in both directions
  • Antidromic (downward) signals
    • Activate GABAergic inhibitory interneurones in the dorsal horn
    • GABA acts on pre- and post-synaptic GABAA and GABAB receptors to inhibit nociceptive transmission (the basis of gate control theory)
  • Orthodromic (upward) signals
    • Modulate brainstem, thalamic and cortical centres involved in pain perception
    • These recruit descending inhibitory pathways (serotonergic and noradrenergic) which further inhibit dorsal horn nociceptive neurones

  • The strength, duration and frequency of the electrical impulses are programmed remotely and can be altered by the patient

Waveforms

  • Conventional (tonic) stimulation produces paraesthesia over the painful area; newer waveforms are largely paraesthesia-free
Waveform Key features
Conventional (tonic)
40-80 Hz
Activates Aβ fibres (gate control); paraesthesia must overlap the painful area; efficacy may wane over time
High frequency
10 kHz
Paraesthesia-free; thought to inhibit dorsal horn neurones without activating the dorsal columns; effective for back pain and painful diabetic neuropathy
Burst Bursts of high frequency spikes mimicking natural neuronal burst firing; mostly paraesthesia-free; may also modulate the affective component of pain
Differential target multiplexed Several simultaneous signals; thought to modulate glial cells as well as neurones
Closed-loop Measures the evoked compound action potential (ECAP) from the dorsal columns after each pulse and adjusts output in real time; keeps stimulation consistent despite movement and posture
Dorsal root ganglion (DRG) stimulation Leads placed in the foramen over the DRG; suited to focal neuropathic pain e.g. lower limb CRPS, groin pain; more posturally stable but technically more demanding


Evidence

  • Long-term efficacy remains debated
    • Trials limited by small numbers, short follow-up and difficulty blinding
    • Recent Cochrane reviews found no clear benefit over placebo, but have been criticised for including older trials and not distinguishing between waveforms
  • Newer waveforms (high frequency, burst, closed-loop) have outperformed conventional stimulation in randomised trials
  • Large registries show sustained improvements in quality of life in many patients

  • Outcome depends on:
    • Patient selection
    • Comorbidities e.g. smoking, psychological distress
    • Surgical technique and operator experience
    • Follow-up after implantation

Complications

  • Loss of efficacy: the main reason for explantation
    • Explantation rates around 10% at 2 years and 20% at 10 years
  • Infection of the implant site (<1%)
  • Lead migration
  • IPG pocket pain
  • CSF leak (particularly DRG stimulation)

Peri-operative management of the patient with a spinal cord stimulator


Assessment

  • If needed, pre-operative discussion with pain/neuromodulation team
  • Establish the device type and manufacturer, and the location of the IPG and leads
  • Generally advised to switch off, although no clear evidence of why

MRI

  • Risks: device movement, induced currents in the leads and radiofrequency heating at the electrode tips causing tissue injury or device malfunction
  • Many devices are labelled MRI-conditional; scanned using low specific absorption rate protocols, with the device switched off and interrogated afterwards
  • MRI-conditionality is not a fixed property of the device
    • Lead impedance can rise over time, so a device may no longer meet scanning criteria
    • Check impedance before scanning, especially >2 years after implantation

Anaesthetic technique

  • Avoid unipolar diathermy; use bipolar where possible
  • Careful positioning to avoid damaging the pulse generator

Risks with neuraxial anaesthesia

  • Damaging the leads
  • Displacing the leads
  • Infection of the leads; no routine antibiotic prophylaxis advised, however

  • Therefore avoid neuraxial anaesthesia

  • Switch device back on
  • No role for management of acute nociceptive pain so should manage this separately as standard